Project Grant K08CA293167
- This $159,255 Project Grant award from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program aims to employ a mixed-methods approach to identify social risk factors associated with variation in pre- and post-operative expenditures and outcomes for episodes of renal colic, a common and costly surgical condition. The award to the University of North Carolina at Chapel...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Virginia a $291,498 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on May 1, 2026, to support structured career development research investigating the impact of obesity and androgen receptor (AR) signaling on BRAF/MEK inhibitor (BRAF/MEKI) resistance in melanoma. Through this five-year award (completion date: April 30, 2031), the principal investigator will conduct research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Research Manpower program (CFDA 93.398), awarded $162,305.00 to the University of Michigan to support mentored research career development in cancer biology. Awarded on August 1, 2025, with a project period extending through July 31, 2030, this grant funds a K08 mentored research career development award for Dr. Peggy Hsu, MD, PhD. The project supports comprehensive investigation into early-stage Anaplastic...
- Federal Grant Award Summary The National Cancer Institute awarded a $212,332 Project Grant to The Leland Stanford Junior University under the Cancer Research Manpower program (CFDA 93.398) effective May 1, 2026, through April 30, 2031. This award supports a K08 mentored research career development grant designed to develop Dr. Aaron Dawes as an independent investigator focused on access and quality of specialty cancer care. The grant provides mentorship, training, and applied research...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Washington $278,494 on August 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support a K08 Mentored Research Scientist Development Award. This five-year project, concluding July 31, 2030, funds the career development and research training of an Assistant Professor of Medicine and primary care physician to become an independent clinician investigator specializing in cancer screening...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Florida a $694,122 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a comprehensive epidemiological study examining the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and thyroid cancer risk. The research project, which began on March 23, 2026, and will conclude on February 28, 2031, addresses critical gaps in understanding thyroid...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $129,058 to the University of Southern California under the Cancer Research Manpower program (CFDA 93.398) on September 1, 2025, to support Dr. Anqi Wang's transition to an independent cancer and molecular epidemiology investigator through a Pathway to Independence Award (K99/R00). The award provides comprehensive research training and career development services, including investigation into the role of loss of Y...
- Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital (MGH) $188,080 under the Cancer Research Manpower program (CFDA 93.398) for a two-year research project beginning August 22, 2025. The award supports a mixed-methods research study titled "Enhancing Access in Pancreatic Cancer: Examining Facilitators and Barriers to Tertiary Referral for Complex Oncologic Surgical Care." The research directly addresses the significant...
- This Project Grant award of $421,525.00, provided by the National Institutes of Health (NIH) through the Trans-NIH Research Support program (CFDA 93.310), supports research to delineate molecular variations within tumors of HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) based on distinct histopathologic features. The project aims to employ machine learning techniques to construct a predictive model using molecular data to classify aggressive tissue phenotypes and predict disease-free...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $169,884 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2025 through June 30, 2027. The award funds biomedical research training and investigator-led research focused on elucidating molecular mechanisms underlying small cell lung cancer (SCLC) pathogenesis and identifying novel therapeutic targets. Specifically, the research...
PREFERENCE-BASED TREATMENT VALUATION IN LOW-RISK THYROID CANCER - SUMMARY/ABSTRACT: THIS CAREER DEVELOPMENT AWARD (K08) ESTABLISHES HEALTH STATE UTILITIES ACROSS SEVERAL ESTABLISHED AND EVOLVING THERAPIES FOR LOW-RISK, SUB-CENTIMETER THYROID CANCER (PAPILLARY THYROID MICROCARCINOMA, PTMC). WHILE SURVIVAL FOR PTMC IS FAVORABLE, ITS TREATMENT CAN INCUR SUBSTANTIAL MORBIDITY AND SOCIETAL COSTS. ACCEPTABLE TREATMENTS INCLUDE ACTIVE SURVEILLANCE, PARTIAL OR TOTAL THYROIDECTOMY, AND RADIOFREQUENCY ABLATION. DUE TO THE DISEASE'S EXCELLENT PROGNOSIS, IT IS UNLIKELY THAT THESE TREATMENTS WOULD YIELD MEANINGFUL DIFFERENCES IN SURVIVAL, HOWEVER POST-TREATMENT EXPERIENCES ARE DIFFERENT. THUS, TREATMENT VALUE IS LARGELY DRIVEN BY PATIENTS' PERCEPTIONS AND PREFERENCES REGARDING THE TREATMENT EXPERIENCE. THIS VALUE MAY BE ESTIMATED THROUGH STATED-PREFERENCE INSTRUMENTS THAT DEFINE THE UTILITY OF PRE-DEFINED HEALTH STATES. THUS FAR, THERE IS LITTLE DATA ON HEALTH STATE UTILITIES IN PTMC, AND IT IS UNCLEAR WHETHER PATIENTS, CLINICIANS, OR THE GENERAL POPULATION ARE THE MOST SUITABLE PARTICIPANTS FOR STUDIES THAT ESTIMATE UTILITY. THE CANDIDATE WILL ADDRESS THESE KNOWLEDGE GAPS BY ESTIMATING THE UTILITIES OF A SERIES OF PTMC CLINICAL VIGNETTES USING A TIME TRADE-OFF PREFERENCE-BASED INSTRUMENT. THESE UTILITIES WILL THEN BE INCORPORATED INTO A MARKOV COST-EFFECTIVENESS MODEL COMPARING SURGICAL AND NON-SURGICAL OPTIONS. SPECIFICALLY, THE CANDIDATE WILL TEST THE FOLLOWING HYPOTHESES: 1) AVERAGE UTILITY FOR THE ACTIVE SURVEILLANCE HEALTH STATE IS NON- INFERIOR TO THAT OF PARTIAL THYROIDECTOMY, 2) TREATMENT COMPLICATIONS SIGNIFICANTLY REDUCE UTILITY, 3) GENERAL POPULATION RESPONDENTS SIGNIFICANTLY UNDERESTIMATE THYROID CANCER UTILITIES RELATIVE TO EXPERIENCED PATIENTS AND HEALTHCARE WORKERS, AND 4) ACTIVE SURVEILLANCE IS MORE COST-EFFECTIVE FOR THE MANAGEMENT OF PTMC THAN SURGERY OR RADIOFREQUENCY ABLATION. THE LONG-TERM OBJECTIVE OF THIS RESEARCH IS TO ESTABLISH PREFERENCE-BASED HEALTH STATE UTILITIES THAT CAN BE USED IN HEALTH ECONOMICS RESEARCH TO OPTIMIZE RESOURCE ALLOCATION IN THYROID CANCER. FOLLOWING A CLINICAL FELLOWSHIP IN SURGICAL ONCOLOGY, THE CANDIDATE WAS APPOINTED ASSISTANT PROFESSOR OF SURGERY AT THE UNIVERSITY OF MARYLAND BALTIMORE. HE HAS SINCE PARTNERED WITH SCIENTIFIC MENTOR C. DANIEL MULLINS, PHD, TO ENGAGE WITH PATIENT AND PHYSICIAN STAKEHOLDERS IN HEALTH SERVICES RESEARCH. THIS K08 IS DESIGNED TO TRANSITION TO RESEARCH INDEPENDENCE THROUGH GRADUATE LEVEL TRAINING IN SURVEY DESIGN, PATIENT-CENTERED OUTCOMES, BIOSTATISTICS, AND HEALTH POLICY. ADDITIONAL PROFESSIONAL COURSES WILL ADDRESS RESEARCH CAREER DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENT. THE APPLICATION DRAWS UPON RESOURCES THROUGH THE SCHOOL OF MEDICINE'S DEPARTMENT OF SURGERY AND THE SCHOOL OF PHARMACY. WITH THE ADVANCED TRAINING AFFORDED BY THE K08, THE CANDIDATE WILL BE POSITIONED TO SUBMIT A COMPETITIVE R01 APPLICATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $279.6k | 6/2/25 | ||
| Not listed | $279.0k | 7/17/24 |